Clinical Trials

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05751044 2025-09-16

HEM-iSMART B

Phase 1/2 Recruiting

26 enrolled

Phase 1 Active not recruiting

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

83 enrolled

Other hematologic neoplasm

Multiple Myeloma, Recurrence

NCT03765541 2025-04-10

DEXAML-03

Phase 3 Terminated

73 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06561854 2024-12-18

FREEDOM

Phase 3 Recruiting

318 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03836014 2024-12-06

CONFIRM

436 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02406222 2024-12-05

MUKseven

124 enrolled

Multiple Myeloma, Recurrence

NCT06050512 2024-11-19

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

150 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03450057 2024-03-29

DARE

38 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT05408026 2023-01-27

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05170789 2022-05-04

ESdRRMM

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT00981708 2021-04-30

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

37 enrolled

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Recurrence

NCT00439296 2021-03-17

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

9 enrolled 12 charts

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

56 enrolled

Multiple Myeloma, Recurrence

NCT01483690 2020-10-27

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

23 enrolled 13 charts

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02952573 2020-09-17

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Phase 2 Terminated

20 enrolled

Multiple Myeloma, Recurrence

NCT00903968 2020-06-02

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

58 enrolled 13 charts

Multiple Myeloma, Recurrence

NCT03492138 2020-05-29

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

5 enrolled

Multiple Myeloma, Recurrence

NCT00440726 2020-02-19

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

31 enrolled 15 charts

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01887587 2020-01-22

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Phase 1 Terminated

5 enrolled 9 charts

Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

48 enrolled 10 charts

Multiple Myeloma, Recurrence

NCT02535806 2019-08-13

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Phase 2 Terminated

2 enrolled 11 charts

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02176213 2019-06-18

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

35 enrolled

Multiple Myeloma, Recurrence

NCT03101579 2019-03-19

Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer

Phase 1 Completed

13 enrolled

CNS

Recurrence, Meningeal Carcinomatosis

NCT00928200 2019-02-19

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Phase 1 Terminated

1 enrolled 7 charts

Hypersensitivity, Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01672736 2018-09-13

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

19 enrolled 10 charts

Multiple Myeloma, Recurrence

NCT02986451 2018-08-14

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT03623087 2018-08-14

SIMPLE Chemotherapy for NK Lymphoma/Leukaemia

Phase 3 Unknown

68 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT02206503 2018-08-02

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

13 enrolled

Multiple Myeloma, Recurrence

NCT01526694 2018-07-03

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

30 enrolled

Multiple Myeloma, Recurrence

NCT01692197 2018-07-03

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Other hematologic neoplasm

43 enrolled 11 charts

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03143036 2018-06-07

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Phase 2 Unknown

100 enrolled

Recurrence, Neoplasms, Plasma Cell

NCT00538824 2018-06-06

DexTR

Phase 2 Terminated

5 enrolled 8 charts